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Abstract
Background: Alternatively-spliced (AS) forms can vary protein function, intracellular localization and post-translational
modifications. AS coupled with mRNA nonsense-mediated decay (NMD) can also control the transcript abundance. Here, we
have investigated the genome-scale conservation of alternatively-spliced NMD candidates (AS-NMD candidates), in
mammals.
Methodology/Principal Findings: We mapped .12 million cDNA/EST library transcripts, comprising pooled data from both
older and next-generation sequencing techniques, against genomic sequences to annotate AS-NMD candidates generated
by in-frame premature termination codons (PTCs), in the human, mouse, rat and cow genomes. In these genomes, we found
populations of genes that harbour AS-NMD candidates, varying in number from ,149 to 2,051 genes. We discovered that a
highly-significant proportion (27%–35%) of AS-NMD candidate genes in mouse, rat and cow, also have human orthologs
targeted for NMD. Intron retention was the most abundant type of AS-NMD, ranging from 43% to 67% of genes harbouring
an AS-NMD candidate. Groupings of AS-NMD candidate genes either with or without intron retentions also have highly
significant AS-NMD conservation, indicating that the trend is not due primarily to conservation of intron retentions. As a
subset, the AS-NMD intron retentions are distinguished from non-retained introns by higher GC content, and codon usage
similar to the usage in protein-coding sequences. This indicates that most of these alternatively spliced sequences have
coded for proteins in the recent evolutionary past. In general, the AS-NMD candidate genes showed a similar pattern of
Gene Ontology functional category enrichments in all four species. Genes linked to nucleic-acid interaction and apoptosis,
and involved in pathways linked with cancer, were the most common. Finally, we mapped the AS-NMD candidates to mass
spectrometry-derived proteomics data, and gathered evidence of truncated polypeptides for at least 10% of all human AS-
NMD candidate transcripts.
Conclusions/Significance: In summary, our analysis provides strong statistical evidence for conservation of functional AS-
NMD candidature across Mammalia for a large subset of genes. However, because codon usage of AS-NMD intron
retentions is similar to the usage in exons, it is difficult to de-couple conservation of AS-NMD-based regulation from
conservation for protein-coding ability, for intron retentions.
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Introduction
Alternative splicing is the generation of multiple transcripts
from a single protein-coding gene. Several studies have shown
that at least half of all human genes undergo alternative splicing
[1,2], although RNA array and sequencing data shows that this
number is likely as high as 94% of genes [3]. Alternatively-spliced
(AS) forms can vary protein function, intracellular localization
and post-translational modifications. Although, in most cases,
protein AS isoforms show only small differences, some isoforms
can lead to large functional variances and even to genetic
disorders [4]. Apparently, alternative splicing can also control
transcript abundance, due to its coupling to mRNA nonsense-
mediated decay (NMD). It seems that at least 10–15% of human
transcripts can be switched off by NMD coupled to alternative
splicing [5].
Nonsense-mediated decay is a eukaryotic surveillance mecha-
nism that detects mRNAs that harbour premature termination
codons (PTCs), and commits these transcripts to rapid decay. One
of the expected physiological consequences of NMD is the
prevention of synthesis of truncated polypeptides, which presum-
ably leads to protection of the cell from resultant deleterious
dominant-negative or gain-of-function effects [6,7]. The biological
importance of NMD is highlighted by the fact that 30% of
inherited genetic diseases are due to PTC, most of which are in
NMD targets [8]. Therefore, the majority of the nonsense-
associated diseases are caused either by an insufficient level of the
functional protein as a result of degradation of a PTC-containing
mRNA, or by generation of a defective truncated protein from a
PTC-containing mRNA that escaped the NMD surveillance [4,8].
In mammalian cells, translation termination codons and exon–
exon junctions are cis-acting elements that allow recognition of
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more than ,50–55 nucleotides upstream of the last exon–exon
junction [8]. The positional information that marks exon–exon
junctions is provided by the components of the splicing-dependent
exon junction complex (EJC) that persist during export, and until
the mRNA is translated [9]. NMD is believed to require three core
UPF factors which are conserved from yeast to humans, namely,
UPF1 (also known as regulator of nonsense transcripts 1
[RENT1]), UPF2 (RENT2), and UPF3 [10]. UPF1 is not only
essential to NMD but is also required for rapid degradation of
histone mRNAs [11].
Here, we have focused on the analysis of orthologous
alternatively-spliced NMD candidates (AS-NMD candidates).
We have annotated and analyzed the occurrence and conserva-
tion of AS-NMD candidates in genes, generated by in-frame
premature stop codons, in four mammalian genomes: human,
mouse, rat and cow. Strikingly, we find highly significant con-
servation of NMD candidature, and also demonstrate that genes
containing an AS-NMD candidate are significantly associated
with specific functional categories of proteins, and of disease-
associated genes.
Results and Discussion
AS-NMD annotation overview
To assess the existence in public databases of alternatively-
spliced forms that are putative candidates for nonsense-mediated
mRNA decay (hereafter termed ‘AS-NMD candidates’), we
developed and applied a pipeline to four mammalian genomes
(human, mouse, rat and cow). This pipeline is described in detail,
in Methods. We annotated AS-NMD candidates as transcripts
containing in-frame premature termination codons (PTCs) .50
nucleotides 59 of the last exon splice junction. In brief, we mapped
the complete corpus of .12 million cDNA/EST transcript library
sequences from several databases (RefSeq, Unigene, dbEST and
H-invitational) against genomic sequences for the four mammals
(human, mouse, rat and cow). This data set contains pooled
transcript data both from older sequencing techniques and from
next-generation sequencing methods. We compared these com-
plete transcript library mappings to mappings to reference mRNA
mappings for each gene, to calculate whether the mapped
expressed sequence is part of an AS-NMD candidate.
The pipeline identified between ,149 and ,2051 genes with
AS-NMD candidates, per genome (Table 1). The number of
supporting cDNAs/ESTs varied between just 190 in rat, to 14,343
in human. The proportions of genes with AS-NMD candidates are
between 1% and 10% of genes in each genome. However, it is
important to be aware that, as for any analysis of transcript data,
the major difference between several studies lies in the number of
transcript sequences considered. For example, Zhang et al. (2009
[12]), reported that, the number of predicted AS-NMD candidates
increased when these authors included predicted RefSeq ESTs in
their analysis.
We classified the AS-NMD candidates according to the type of
events that they present: IR, intron retention; CSE, cassette exon;
ASD, alternative splicing donor; ASA, alternative splicing acceptor
(Tables 2–3). Surprisingly, IR was the most abundant event in all
genomes. It varied from 43% to 67% of all genes that harbour AS-
NMD candidates. ASA was the second most abundant event
(19%–32%). Due to the large number of IRs, we present below a
set of analyses to verify whether or not—as a population—the IRs
are artifacts derived from unprocessed or partially processed pre-
mRNAs.
In a previous work, we studied duplicated pseudogenic exons (i.e.,
YEs, exons disabled by frameshifts and premature termination
codons) on the same four genomes of our present study [13]. In order
to evaluate the contribution of exon duplication and pseudogeniza-
tion to the production of AS-NMD candidates, we compared the list
of genes bearing a YE and the list of AS-NMD candidates. Wefound
that only 7 genes are common to both lists in human, and 3 genes in
mouse. Thus the vast majority of AS-NMD candidates are not made
through exon duplication, followed by disablement. We also cross-
referenced our gene list with the Ensembl pseudogenes annotation
(Build 52) to verify whether any of our genes was annotated
exclusively as a pseudogene. No pseudogene was found in our list,
indicating that they are all alternatively-spliced forms of protein-
coding genes. We additionally compared our list of AS-NMD
candidates with the general annotation of the human genome in the
Ensembldatabase(www.ensembl.org).Wefoundthatasmallfraction
(321 genes, ,15%) in our list were also annotated as NMD-targeted
transcripts by Ensembl.
Also, we wished to investigate whether AS-NMD events are
associated with lower or higher gene expression levels. To do this,
we used the number of ESTs/cDNAs as a broad indicator of
expression level. In general, AS-NMD is associated with lower
numbers of mapped ESTs/cDNAs (Supplementary Table S1A).
For example, in human there are ,75 transcripts mapped per
gene, compared with ,7 per gene for genes with AS-NMD events.
Also, the substantial majority (.88%) of AS-NMD candidates
have low numbers of ESTs/cDNAs (#3 mapped sequences,
Supplementary Table 1B).
Table 1. Summary of the AS-NMD candidates.
Genomes
(1) AS
events
(2) EST/cDNA
transcripts
supporting
the AS
(3) Genes
with an
AS-NMD
candidate
(4) Number of
(1) that are only in
the Refseq or
Unigene databases
(5) Proportion of (3)
that have orthologs* in
the human genome
(6) AS-NMD candidate
genes with an orthologous
AS-NMD candidate in the
human genome*
Homo sapiens 2536 14343 2051 (9.8%){ 12/2536 (0.5%) -------- --------
Mus musculus 1211 1628 1069 (4.6%){ 23/1211 (1.9%) 970/1069 (91%) 262/970 (27%) =
Rattus norvegicus 166 190 149 (0.84%){ 6/166 (3.6%) 129/149 (87%) 45/129 (34%) =
Bos taurus 374 600 342 (1.8%){ 4/374 (1.1%) 297/342 (87%) 105/297 (35%) =
{Percentage of the total number of known genes based on Ensembl build 52.
{{Percentage of retained introns whose length is a multiple of 3.
*Orthology was based on the relationship one-to-one between a human transcript and a transcript from the other genome according to Ensembl annotation.
=Significant by a hypergeometric probability test with P #10
210. We calculated the probability of picking the observed number of AS-NMD candidates in the other
mammals that are conserved in human, from the total population of human genes.
doi:10.1371/journal.pone.0011695.t001
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We extracted orthology information about genes from the
Ensembl database. Each AS-NMD candidate found in one of the
three other species (mouse, rat and cow) was used as a query to
find the corresponding ortholog in the human genome. Only
matches annotated as ‘one2one’ (i.e., the transcript is bi-
directionally the best match between the two genomes) were
counted as true orthologs.
We examined the human conservation of genes that harbour
AS-NMD candidates in the three other genomes (mouse, rat and
cow) (Tables 1–2). A large proportion of these genes have clear
single orthologs in the human genome (87–91%). Of these
orthologous human genes, 27–35% also harbour orthologous
AS-NMD candidates. (See the Supplementary Table S2 for the
full list of the AS-NMD candidate orthologs in each species, and
Supplementary Table S3 for a complete breakdown of the
different types of AS-NMD and their conservation patterns.) This
degree of conservation is highly significant according to hypergeo-
metric probability (P-values ,10
210, treating the conserved cases
as a sample of all human genes that have AS-NMD candidature).
Additional calculations for the number of conserved cases that
would arise from random placement of the NMD features in
human introns, also indicate that these results are highly
significant. For example, for the smallest sample (human intron
retentions whose NMD candidature is conserved in rat, 92 cases),
we generated 1,000 random samples of 92 transcripts, with
appropriate weighting for the number of introns in each transcript.
These weightings were calculated simply through random
sampling from the total list of introns in all human genes.
Through this sampling procedure, given the frequency of NMD
events in human, we found that only 1.3(62.3) AS-NMD
candidates would have conserved AS-NMD candidature by
chance between human and rat (32 conserved cases are observed,
Table 2).
This significant conservation of AS-NMD candidature arises
both for the whole data set of AS-NMD candidates (Table 1), and
for the subset that comprise intron retentions (IRs) only (Table 2).
In addition, AS-NMD candidate genes without AS-NMD intron
retentions, also exhibit highly significant conservation (not
tabulated explicitly in Tables 1–2; P,,0.000001 for rat, mouse
and cow using hypergeometric probability, as described above).
Interestingly, however, only ,13–22% of the IRs are conserved in
the same position in the gene, indicating that there may just be
selection pressure to maintain the NMD status, and not a specific
retained intron.
Two models for AS-NMD candidates have recently been
discussed, the ‘spurious transcript’ model, and the ‘regulatory
model’ [12]. In the ‘spurious transcript’ model, the NMD function
is to degrade costly-to-make and potentially toxic unwanted
transcripts. Another prediction of this model is that AS-NMD
should arise for rare transcripts, and be more common in recently-
Table 2. Summary of the AS-NMD candidates involving intron retentions (IRs).
Genomes
(1) EST/cDNA
transcripts
supporting the IR
(2) Genes with
an AS-NMD
candidate
involving an IR
(3) IRs with
lengths that
are multiples
of 3n{{
(4) Orthologs*
in the human
genome
(5) AS-NMD candidate
genes with an
orthologous AS-NMD
candidate in the human
genome*
(6) Proportion of
cases in (5) that
are in the same
position in the
gene {{{
Homo sapiens 2117 884 37% -------- -------- --------
Mus musculus 725 475 28% 440 153/475 (35%) === 20/153 (13%)
Rattus norvegicus 123 95 36% 92 32/95 (35%) = 7/32 (22%)
Bos taurus 428 231 30% 211 85/231 (40%) == 17/85 (20%)
{Percentage of the total number of known genes based on Ensembl build 52.
{{Percentage of retained introns whose length is a multiple of 3.
{{{The percentage is based on the number of AS-NMD candidates with an orthologous AS-NMD candidates in the human genome (Table 1).
*Orthology was based on the relationship one-to-one between a human transcript and a transcript from the other genome according to Ensembl annotation.
= Significant by a hypergeometric probability test with P #10
210. We calculated the probability of picking the observed number of AS-NMD candidates in the other
mammals that are conserved in human, from the total population of human genes.
doi:10.1371/journal.pone.0011695.t002
Table 3. Number of events per genome.
Events Homo sapiens Mus musculus Rattus norvegicus Bos taurus
IR
{ 884 (43%)* 475 (44%) 95 (63%) 231 (67%)
CSE
{ 444 (21%) 137 (12%) 10 (6%) 27 (8%)
ASD
{ 592 (29%) 247 (23%) 26 (17%) 49(14%)
ASA
{ 616 (30%) 352 (32%) 35 (23%) 67 (19%)
Avg. IR size 259 nt 171 nt 189 nt 188 nt
% id. with a human Ortholog
a -------- 84% 85% 88%
IR (intron retained); CSE (Cassette exon); ASD (alternative splice donor); ASA (alternative splice acceptor).
{Values based on the number of genes.
*The percentage does not add up to 100 since one gene can have more than one event simultaneously.
aValues based on protein sequence.
doi:10.1371/journal.pone.0011695.t003
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The alternative model is the ‘regulatory model’. In this model, the
function of the NMD is to modulate gene expression. Although
this model does not preclude multiple AS forms, it does not predict
them. The regulatory model predicts that AS-NMD candidature
should be conserved among distant species [12].
Our findings on AS-NMD candidate conservation are support-
ive of the regulatory model of NMD for a large subset of genes.
Several previously well-documented examples have leant support
to this theory. For instance, the NMD control of splicing in the
splicing regulator (SR) genes, one of the most extensive studied
cases of NMD controlling gene expression, is conserved across
mammals and plants [14].
Our results seem to disagree with a previous study that found
only ,8% AS-NMD candidates in a pair of orthologs between
human and mouse [12]. However, a closer look shows that our
data is comparable. The authors in this previous study used only
RefSeq mRNAs in their analysis. When we considered only
RefSeq mRNAs, in our analysis, the number of pairs of
orthologous AS-NMD candidates between human and mouse
was 7%, in agreement with the previous study [12].
Intron Retention (IR) Analysis
Intron retention is one of the least studied AS forms. One of the
major reasons for this is the difficulty of differentiating real IRs
from artifacts derived from unspliced or partially spliced pre-
mRNA [15,16]. However, previously it has been shown that
retained introns seem to present sequence characteristics that
distinguish them from non-retained introns, and also from protein-
coding exons. These features include their average size, GC
content and codon usage. In some cases the retained intron can
also encode a protein domain or part of a domain [16–18].
Here, we have assessed the AS-NMD retained introns in our
data set for any evidence of selection pressures. One such source of
evidence is deviation in GC content because of selection for
transcriptional efficiency [15,16,19]. We analyzed deviation in GC
content in the retained introns, as a function of intron length
(Figure 1), to avoid GC content bias due to the size of the
sequences. Firstly, we examined the following three data sets:
retained introns, exons bordering retained introns, and non-
retained introns. We divided the three data sets into categories
according to their sequence length (Figure 1). Non-retained introns
showed a statistically significant lower GC content in all classes of
size compared with retained introns and exons (x
2=18.9,
p,0.0001; x
2=25.6, p,0.0001, respectively). In contrast, re-
tained introns showed a similar GC content compared with exons
(x
2=0.67, p=0.41). For comparison, we also included retained
introns in genes that are orthologous AS-NMD candidates
between human and mouse (Figure 1). Although, there is no
retained intron shorter than 100 kb, all retained introns classes
behaved more similarly to exons (x
2=0.21, p=0.9) than to non-
retained introns (x
2=34, p,0.0001).
To evaluate the codon usage of the retained introns we used a
test described by Galante, et al. (2004, [15]) (for more details see
the Methods section). We created 100 random sets of exons
bordering retained introns and non-retained introns, each set
Figure 1. Mean GC content of retained introns, exons bordering retained introns and non-retained introns in human AS-NMD
candidates. The data sets was divided into five categories to avoid bias due to their length. The data set of ‘Non-retained introns’ was generated by
randomly picking a non-retained intron from the set of genes that contain retained introns, so that the same number of sequences is in each bin. In
addition, we included bars in the plot for ’Retained introns that are conserved between human and mouse.
doi:10.1371/journal.pone.0011695.g001
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intron set). We then put each sequence in frame and performed a
pairwise comparison of the total codon table (61 amino acids) of
the three data sets (Table 4). We find that retained introns and
exons share more similarities with each other than with non-
retained introns (Table 4). This indicates that the retained introns
may have had phases of protein-coding ability before acquiring
premature stop codons, or may still be protein-coding. The fact
that codon usage of AS-NMD intron retentions is similar to the
usage in exons indicates that it is difficult to de-couple AS-NMD-
based regulation from the evolutionary dynamics of protein-
coding intron retentions.
We further analyzed the occurrence of stop codons in the
retained introns (RIs), to analyse whether they may be able to
become protein-coding through changing readong frames. On
average, 95% of the RIs have a PTC in more than one frame and
90% of the RIs have a PTC in all three frames. Therefore, they
are generally unlikely to be present in a functional, non-truncated
protein.
We also assessed the ability of the AS-NMD candidate IRs to
encode protein domains. To do this, we extracted three set of
sequences: intron retentions, exons and sequences comprising retained
introns and their 59 and 39 exons (‘E-IR-E’ sequences). These three
sequence sets were compared against the Pfam database (as
described in Methods). In total, we found 27 retained introns (in 27
genes) coding for a protein domain (17% of a total of 155 genes).
Ten out of 27 retained introns encoded part of a domain also
encoded by one of the flanking exons. Retained introns encoded
for a different domain compared with their flanking exons in 14
cases and in three cases, only the retained intron encoded a Pfam
domain. There was no case where the whole E-IR-E sequence
encoded a domain.
The majority of the AS-NMD candidate ortholog pairs between
human and mouse (153 out of 262) presented an IR in both
species. As discussed above, the large number of AS-NMD
candidates that are orthologously conserved between human and
mouse is consistent with a widespread conserved mechanism to
control gene expression through NMD.
We also annotated retained introns with PTCs that do not
target the mRNA for NMD (termed ‘non-NMD’ retained introns)
(Table 5). The number of genes bearing a non-NMD retained
intron was between 2 and 4-fold higher than the number of genes
with an AS-NMD candidate (the difference is statistically
significant for all four genomes by x
2 test with P#10
27). This
indicates an apparent selection against PTC in NMD areas, and
was also observed by us in a previous work [13], and by other
authors as well [15]. The average size of non-NMD intron
retentions is greater than AS-NMD candidates, although only in
humans, this difference is statistically significant (x
2=19,
p,0.0001) (Table 5).
Functional Annotation
We wished to determine the functional linkages of genes with
AS-NMD as a subpopulation of all genes in an organism. Using
the webtool FatiGO [20], we annotated the most common Gene
Ontology terms [21], Biocarta pathways (http://www.biocarta.
com/genes/index.asp), TRANSFAC [22] transcription factors,
and KEGG [23] terms in each genome, and calculated which
terms are overrepresented in genes with AS-NMD candidates.
Significant over-representation was calculated using a Fisher’s
exact test with P’ value threshold of ,0.05, and a correction to P’
for multiple hypothesis testing [20].
The term ‘Nucleotide binding’ (GO:0000166) seems to be
ubiquitous for AS-NMD candidates in the four genomes. Other
abundant terms include those related to DNA interaction, DNA
damage, cell cycle control and apoptosis (Table 6). Transferase
and hydrolase activities were also common. The pattern of over-
and under-representation of GO terms was similar for all four
species. (The GO terms were simultaneously statistically significant
in the four genomes only for non-corrected P values; see Table 6
for details.) This result shows that NMD may target different genes
in different species, but these genes often belong to the same
functional categories.
We also performed a census of the most common protein
domains in the genes with AS-NMD candidates (with all domains
counted only once per gene). The most common Pfam protein
domain was the WD-40 domain (except in rat) (Supplementary
table S4). This domain is known to be involved in several cellular
functions, such as signal transduction, cell-cycle control and
apoptosis [24]. (Supplementary table S4).
In cow and rat, cancer-related pathways are significantly
enriched (for P-values corrected for multiple hypothesis testing)
according to KEGG classification. In mouse, besides cancer, AS-
NMD candidates related with apoptosis are the most abundant.
Human AS-NMD candidates are enriched for ‘glycine, serine and
threonine metabolism’, ‘epithelial cell signaling in Helicobacter
pylori infection’ and ‘androgen and estrogen metabolism’ KEGG
pathways (Supplementary table S5). One role of NMD seems to be
to protect individuals that are heterozygous for a PTC-containing
allele; such an NMD-based mechanism has been demonstrated for
genes associated with anemia, breast cancer, and diabetes type II
[8,25].
In the BioCarta pathway classification, we found five pathways
in humans, enriched for AS-NMD candidates: antigen processing
and presentation, inhibition of cellular proliferation by Gleevec,
cell-to-cell adhesion signaling, integrin signaling pathway and role
of Ran in mitotic spindle regulation (supplementary table S6).
Supplementary Figure S1 shows an example of a Biocarta
pathway enriched for AS-NMD candidates. The drug Gleevec
(also known as imatinib mesylate or STI-571) is considered one of
Table 4. Codon usage comparison of retained introns, exons
and non-retained introns in human AS-NMD candidates.
Retained introns
and Non-retained
introns
Retained
introns and
Exons
Non-retained
introns and Exons
Codon table
(Average x
2)
*
13246282 950686 25316310
*Comparison of the entire codon usage table (61 codons, 60 degrees of
freedom) among three datasets.
doi:10.1371/journal.pone.0011695.t004
Table 5. Retained introns (IRs) with a premature stop codon
that not target the mRNA for NMD.
Homo
sapiens
Mus
musculus
Rattus
norvegicus
Bos
taurus
Retained introns 5029 970 261 522
Number of genes with a IR. 3111 770 205 416
Avg. size of IR. 421 nt 180 nt 210 nt 202 nt
IR (3n){ 33.5% 34% 36% 35%
{Percentage of retained introns whose length is multiple of 3.
doi:10.1371/journal.pone.0011695.t005
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CML, chronic myeloid leukemia. Gleevec acts on a molecular
target by a mechanism that is more specific to cancer cells than
traditional cytotoxic treatments [26]. We found four key genes in
the ‘Inhibition of cellular proliferation by Gleevec’ pathway that
are targets for NMD: breakpoint cluster region (BRC), mitogen-
activated protein kinase 1 (MAP3K1), v-akt murine thymoma viral
oncogene homolog 1 (Akt-1), and c-fos FBJ murine osteosarcoma
viral oncogene homolog (FOS). The loss of expression of these
genes is linked with several diseases and in some cases can be
lethal. For example, it was found that loss of Akt1 resulted in
defective ischemia and Vegf-induced angiogenesis and severe
peripheral vascular disease in mice [27]. Loss of Mekk1 expression
resulted in a greater apoptotic response of cells to hyperosmolarity
and microtubule disruption [28].
We also calculated enrichments of transcription factor binding sites
in the promoters of genes that target AS-NMD candidates
(Supplementary Table S7). In human, the most significantly-enriched
transcription factor binding site was for E2F1. Merdzhanova et. al.
(2008, [29]),studied the associationof E2F1and the splicing regulator
SC35 (a gene with an AS-NMD candidate). According to these
authors, E2F1 upregulates the expression of SC35 in response to
DNA-damaging agents; they also show that SC35 is required for
apoptosis in response to these agents. The apoptotic mechanism
involves the pro-apoptotic alternative splice form of the gene Bcl-x
(also a AS-NMD candidate) that is in turn controlled by SC35 [29].
Expression of the NMD-targeted form of SC35 could switch on the
overexpression of anti-apoptotic splice variants of genes like Bcl-x and
caspase. Such alteration is believed to contribute to the resistance of
tumor cells to chemotherapy [30,31].
We compared the representation of AS-NMD candidate genes
in the OMIM database with the overall representation of the
human genome in the same database. The difference of
representation of the two sets in the OMIM database is highly
statistically significant (x
2=129, p,0.0001). While 35% of the
human gene complement is present in OMIM, the proportion of
human AS-NMD candidate genes in OMIM is 50%. NMD-
associated diseases often result from insufficient levels of full-length
protein. Therefore, these diseases are generally due to two defects
in gene expression: degradation of the newly synthesized PTC-
containing mRNA by NMD, and failure of the abnormally low
level of PTC-containing mRNA that escaped NMD to generate
full-length, and thus, functional protein.
In summary, these analyses indicate that similar functional
categories and protein domains are enriched in genes with AS-
NMD in all four genomes. Also, in general, KEGG pathways
related to cancer are enriched, and AS-NMD genes are more
likely to be associated with diseases in the OMIM database. We
discussed a specific example of a pathway with several AS-NMD
candidates, that is important for cancer treatment, that we found
in the Biocarta classification.
Mapping AS-NMD candidates to the MS PRIDE database
Since 5 to 25% of PTC-containing mRNAs fail to elicit NMD
and are consequently translated into truncated proteins [32],
several therapies have been developed specially to suppress in-
frame PTC [33,34]. Some criticism of nonsense-suppressor
therapies is that new diseases can be created even if only a single
C-terminally extended protein from one of the many cellular
transcripts were to accumulate to a toxic level. Furthermore,
another problem is the unknown consequences of failure to
eliminate naturally-occurring NMD targets [35].
To quantify the frequency with which the expressed AS-NMD
candidates escape NMD and are translated into proteins we
mapped each human translated AS-NMD candidate to ,550,000
peptides extracted from the repository of mass spectrometry-
derived proteomics data (PRIDE) [36].
After filtering out the matches for uniqueness and size (peptides
less than 7 amino acids long and peptides matching another gene
were discarded) we found 205 AS events in 194 genes with peptide
matches in the alternatively-spliced area (hereafter referred as AS-
NMD-PRIDE genes) (Table 7). This is ,10% of the total number
of genes targeted to NMD (Tables 1–2).
The majority (71%–81%) of the human AS-NMD-PRIDE
genes possess an ortholog in one of the other species studied. We
also compared the ‘AS-NMD-PRIDE’ genes with the remaining
AS-NMD candidates (AS-NMD candidates with no match in
PRIDE database). Surprisingly, the proportion with conserved AS-
NMD orthologs was nearly the same for both sets of genes. For
example, in the AS-NMD-PRIDE set 18%, 3% and 8% of the
human orthologs in mouse, rat and cow respectively were also
targeted for NMD. For the remaining AS-NMD candidates, the
Table 6. Most represented GO terms per genome.
Homo sapiens Mus musculus Rattus norvegicus Bos taurus
GO Molecular Function Level 3
Hydrolase activity (GO:0016787)
Nucleotide binding (GO:0000166)
Lyase activity (GO:0016829)
Oxidoreductase activity
(GO:0016491) GTPase regulator
activity (GO:0030695)
Nucleotide binding (GO:0000166)
Hydrolase activity (GO:0016787)
Transferase activity (GO:0016740)
Helicase activity (GO:0004386)
{Oxidoreductase activity
(GO:0016491){
Transferase activity (GO:0016740) { Amine
transporter activity (GO:0005275) { Organic
acid transporter activity (GO:0005342) {
Nucleotide binding (GO:0000166) { Enzyme
activator activity (GO:0008047) {
Structural constituent of ribosome
(GO:0003735) { Nucleotide binding
(GO:0000166) { Selenium binding
(GO:0008430) { Transferase activity
(GO:0016740) { Helicase activity
(GO:0004386) {
GO Molecular Function Level 4
Transferase activity, transferring
phosphorus-containing groups
(GO:0016772) Purine nucleotide
binding (GO:0017076) Translation
factor activity, nucleic acid binding
(GO:0008135) Carbon-carbon lyase
activity (GO:0016830) RNA binding
(GO:0003723) {
Purine nucleotide binding
(GO:0017076) Transferase activity,
transferring phosphorus-containing
groups (GO:0016772) Hydrolase
activity, acting on acid anhydrides
(GO:0016817) Ligase activity, forming
carbon-oxygen bonds (GO:0016875)
RNA binding (GO:0003723) {
Hydrolase activity, acting on glycosyl bonds
(GO:0016798) { Transferase activity,
transferring phosphorus-containing groups
(GO:0016772) { Purine nucleotide binding
(GO:0017076) { Carboxylic acid transporter
activity (GO:0046943){ GTPase activator
activity (GO:0005096) {
Purine nucleotide binding (GO:0017076){
Hydrolase activity, acting on glycosyl
bonds (GO:0016798) { Calmodulin
binding (GO:0005516) { Enzyme binding
(GO:0019899) { Oxidoreductase activity,
acting on peroxide as acceptor
(GO:0016684) { ATPase inhibitor activity
(GO:0042030){
{Statistically significant (but for P value non-corrected for multiple hypotheses only).
doi:10.1371/journal.pone.0011695.t006
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than half of the AS-NMD-PRIDEs come from AS forms
containing retained introns (56%), while in AS-NMD candidates
the frequency is 47%. Interestingly, the retained introns with
PRIDE matches do not show any significant deviation with respect
to GC% (Supplementary Table S8).
The AS-NMD-PRIDE set of genes were significantly enriched
for ‘protein metabolic process’ (GO:0019538), ‘cellular macromolecule
metabolic process’ (GO:0044260) GO biological process and ‘structural
constituent of ribosome’ (GO:0003735) GO molecular function,
compared with the whole human genome. The last GO term
was also enriched when AS-NMD-PRIDE set of genes was
compared with the general AS-NMD candidates set.
Among the genes present in the ‘structural constituent of ribosome’
GO term we found two cases in which the ortholog gene was also
targeted for NMD: the gene RPL5 in mouse and the bovine
RPS13. The human and cow RPS13 presented a retention of
intron 1 that targets its mRNA for NMD. Using the ECR browser
[37] to generate an alignment of the RPS13, we could observe a
high GC content in the intron 1 (.65%), as well as small size
(141 nt), and a high conservation among human, mouse and cow
(Figure 2). Taken together, these are the typical symptoms of a
non-spurious retained intron. Recent study showed that the
presence of intron 1 in the human RPS13 reduced its expression
by a factor of four [38]. Apparently, the gene RPS13 can regulate
its protein level via a feedback mechanism. The ribosomal protein
S3 was found to inhibit the excision of the intron 1 from the rpS13
pre-mRNA. This protein binds specifically the intron fragment
near the 59 and 39 splice site, therefore conferring protection
against cleavage by ribonucleases [38]. Although the extrariboso-
mal function of rpS13 is still unclear, a study suggested that this
gene (along with rpL23) promotes multidrug resistance in gastric
cancer cells by suppressing apoptosis [39]. A similar pattern of
proteins regulating their own splicing and generating aberrant
mRNA was also found in Saccharomyces cerevisiae [40] and in C.
elegans [41] which suggests that NMD plays a important role in
gene regulation. In Figure 3, we have illustrated five other
examples of retained introns, that are conserved in mouse; note
that each of these cases is in a gene structure with a large number
of introns.
Conclusions
In this work, we have annotated and analyzed alternative
splicing coupled with nonsense-mediated decay in four mamma-
Table 7. Comparison between human AS-NMD candidates with and without matches in PRIDE database.
Homo sapiens AS events
ESTs/cDNAs/
mRNAs sup
porting the AS
Number
Genes
Orthologs
in another
genome
AS-NMD candidates with an
orthologous AS-NMD
candidate in another genome
AS-NMD
candidates
with a IR
AS-NMD candidate
with match in PRIDE
205 385 194 159 (mouse) 139 (rat)
156 (cow)
30 (mouse) 5 (rat)
13 (cow)
110
AS-NMD candidate
without match
2331 13958 1857 1560 (mouse) 1425 (rat)
1478 (cow)
232 (mouse) 40 (rat)
92 (cow)
884
doi:10.1371/journal.pone.0011695.t007
Figure 2. The RPS3 gene. (A) Conservation of the gene RPS13 among human, mouse and cow. Yellow bars, UTRs; Blue bars exons; Orange bars,
Intron; Green bar, repetitive elements. The conserved retained intron is indicated (braces). (B) Alignment of UTR-Exon1-Intron1-Exon2-Intron2. The
start and end of the conserved intron is indicated by vertical bars.
doi:10.1371/journal.pone.0011695.g002
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alternative splicing coupled with NMD occurs in 2 to 10% of the
known annotated genes in each genome, and that there is a highly
significant conservation of AS-NMD candidature in genes across
the four mammals. Human AS-NMD candidates seem to have a
large number of orthologs in mouse (,82%), and at least 15% of
those orthologs are also AS-NMD candidates in another species.
We think that, in the future, increased sampling of transcripts will
lead to increased discovery of conservation of specific AS-NMD
events between different organisms. It is possible that there are
many such AS-NMD features in genes, but that we have not
detected all of them because of insufficient sampling. Also, the AS-
NMD events may be designed to be easily turned ‘on’ or ‘off’ (i.e.,
the ability to include the AS-NMD feature may be easily modified
over evolutionary time).
Although we only analyzed AS-NMD candidates with in-frame
PTCs in this study, we have demonstrated that intron retention
plays an important role in producing AS-NMD candidates in all
four species. A large fraction (58 to 81%, depending on the species)
of conserved AS-NMD candidates are intron retentions. The
retained introns also possess features that distinguish them from
non-retained introns, such as smaller size, higher GC content and
codon usage similar to exons. The latter indicates that retained
introns tend to have phases of protein-coding ability before
acquiring stop codons; it is thus difficult to de-couple this
phenomenon from the additional role of such transcripts as
NMD candidates.
The AS-NMD candidate genes also showed a similar pattern of
Gene Ontology enrichment in all four species. Genes linked to
nucleotide interaction and cell fate (apoptosis) were the most
abundant to produce AS-NMD candidates. KEGG and Biocarta
pathways also showed an over-representation of pathways linked
with cancer and genetic disorders for such AS-NMD-making
genes. Thus, NMD appears to have a significant role in controlling
the expression of aberrant proteins in these pathways, and
prevents their deleterious effects.
We gathered evidence of translation of at least 10% of all AS-
NMD candidates in the human genome. Such cases, are not,
however, especially conserved in comparison to other AS-NMD
candidates. We cannot determine here whether such truncated
proteins have a function in human cells; they may just be ‘junk’
polypeptides that are degraded at a later stage. However, because
retained introns with premature stop codons have similar codon
usage to exons, this strongly indicates that some NMD substrates
have at least been protein-coding in the recent evolutionary past.
Furthermore, in one of the AS-NMD candidates, the gene
RPS13, we found evidences of a conserved mechanism of
autoregulation, between human and cow, in which the protein
inhibits the excision of one of its introns, creating a splice form that
is targeted for NMD.
Alternative splicing coupled with NMD seems to act on a wide
range of genes, but, however, only in a few significantly over-
represented functions across mammalian genomes. The data
herein provide statistical evidence for conserved regulation via
AS-NMD candidature across Mammalia, for a large subset of
genes.
Methods
Genome data
The genome sequences and annotations of four mammals
(human, cow, mouse and rat) were downloaded from the Ensembl
Web site (http://www.ensembl.org), in March 2009. The genome
assemblies are: human=Homo_sapiens.NCBI36.52; cow=Bos_
taurus.Btau_4.0.52; mouse=Mus_musculus.NCBIM37.52 and
rat=Rattus_norvegicus.RGSC3.4.52. These genomes were cho-
sen based on two criteria: (i) high coverage (.7X), and (ii) large
number of cDNAs and ESTs sequences available (covering .85%
of annotated genes).
The cDNA/EST/mRNA data were downloaded from the
Refseq database (ftp://ftp.ncbi.nih.gov/refseq), the H-invitational
database (http://h-invitational.jp/hinv/ahg-db), the Unigene
compendium (ftp://ftp.ncbi.nih.gov/repository/Unigene; Build
#217) and the dbEST data set (ftp://ftp.ncbi.nih.gov/reposito-
ry/dbEST/), in March 2009. At the time of downloading, the
dbEST database contained deposited data from next-generation
sequencing in addition to EST sequencing data from older
techniques.
Figure 3. Percentage of identity in a window of 20 nucleotides of five pairs of AS-NMD candidates orthologs between human and
mouse. The red bar above each graph represents the retained intron in the mouse AS-NMD candidate (IR = retained intron in the human genome).
doi:10.1371/journal.pone.0011695.g003
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premature stop codon targeting the mRNA for nonsense-
mediated decay
(I) Reference identification. We identified the reference
mRNA (an mRNA that aligns with 100% coverage and identity to
an annotated protein) of each human, mouse, rat and cow
transcripts. A bl2seq alignment [42] was performed between
mRNAs from Refseq, Unigene and H-invitational (human
genome only) and each protein in the Ensembl database.
Transcripts without a reference mRNA were discarded from our
analysis.
The genomic loci were identified and extracted from the
Ensembl annotations and expanded by 500 nucleotides 59 and 39
of the locus, to allow for variation in the transcriptional start and
polyadenylation sites [25]. Each reference mRNA was aligned
with its genomic locus using GMAP [43].
(II) Mapping. To identify AS forms we aligned each genomic
locus that has a reference mRNA, against all mRNAs and ESTs/
cDNAs from the Refseq, Unigene, dbEST and H-invitational
databases (this last database is for human only). Each alignment
was parsed into a set of splice junction coordinates. Alignments
where the coverage was ,0.96 of the length of the mRNA or EST
and ,98% sequence identity were discarded. We also discarded
ESTs that aligned to the opposite strand. In cases were a mRNA/
cDNA/EST mapped to more than one gene, the best mapping
was considered the correct one. If a mapping presented the same
percentage of identity and coverage to more than one gene, the
mapping was discarded.
(III) Coding sequence (CDS) annotation. We performed a
new round of alignments to identify the coding region (CDS) of
each mapped transcript. Using the program Exonerate [44], we
aligned each transcript retrieved from the previous mapping,
against the encoded protein extracted from the Ensembl
annotation.
(IV) Nonsense-mediated decay targeting annotation. We
compared each mapped splice junction with the reference mRNA
splice junctions. If a splice form mapped .10 nt from the reference
junction, it was annotated as an alternative splice form. We verify
the presence of PTCs targeting the mRNA/EST for NMD, using
the 55-nucleotide rule [6]. Using the CDS annotation, we checked
the mRNA/EST sequence for an in-frame stop codon 55
nucleotides or more 59 to an exon-exon junction.
Intron retention (IR) analysis
To verify whether genes targeted for NMD due to IR were
caused by an unspliced or partially-spliced pre-mRNA, we
analyzed several features of our sequences and compared them
with their flanking exons, and with non-retained introns. Some of
our analysis followed the analysis described by Galante, et al.
(2004) [15].
Codon Usage/Bias. We assess the codon usage and codon
bias of retained introns, exons bordering retained introns and non-
retained introns. We only used AS-NMD candidates with at least
one full length cDNA containing the IR. The frame of non-
retained introns and retained introns was defined by the frame of
the exon 59 to it.
We analyzed the general codon bias of all 61 codons in the three
sets. We performed 100 pairwise comparisons of the distribution of
16,970 codons (number of codons in the retained intron set), along
with 61 possible codons to calculate the average x
2 and standard
deviations thereof.
Pfam domain analysis. DNA sequences from retained
introns, exons bordering retained introns and exon–intron retention–
exon (‘E-IR-E’) sequences were compared to the Pfam database
using BLASTx program (e-value 10
22). Only genes with a full-
length cDNA/EST and with a retained intron entirely in the CDS
were used in this analysis (155 in total).
GC content. To assess the GC content of the retained
introns, exons bordering retained introns and non-retained
introns, we created three datasets with the same number of
sequences divided into five classes according to their length. The
non-retained introns were randomly picked from the set of genes
containing the retained introns in order to avoid any kind of bias
toward a specific type of gene. A x
2 test was used to evaluate the
differences between each dataset.
Orthologs
The information about pairs of orthologs between human and
the other species was extracted from the Biomart query system in
the Ensembl database. We only considered two genes as being
orthologs when they mapped in a one-to-one way.
Functional Annotation
Gene Ontology (GO [21]) functional categories, transcription
factors TRANSFAC [22] and KEGG [23] and BioCarta (http://
www.biocarta.com/genes/index.asp) terms, were retrieved from
the FatiGo database [20]. We performed a functional enrichment
analysis of our list of AS-NMD candidates against the whole
genome annotation of each species. Significant overrepresentation
was calculated using a Fisher’s exact test with P’ ,0.05, and a
correction to P’ for multiple hypothesis testing [20]. Human AS-
NMD candidates were cross-referenced with the NCBI OMIM
database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=omim),
to identify linkage to genetic disorders.
Mapping peptides from mass spectrometry-derived
proteomics data to AS_NMD candidates
We mapped all human AS-NMD candidates to .600,000
peptides from mass spectrometry, extracted from the PRIDE
database [36]. These peptides are derived from a wide variety of
human samples, as follows: blood plasma, peripheral blood
mononuclear cells, erythrocytes, platelets, brain, HeLa cells, K-
562 cells, HEK-293 cells, melanocytes, placenta, breast cancer
cells, bone marrow cancer cells, JURKAT cells, liver, cerebrospinal
fluid, heart and saliva. Each transcript was translated in the 3
frames and checked against the PRIDE peptides. We derived a Perl
program to check the occurrence of peptides upstream of the PTC.
We filtered out any matching peptide smaller than 7 amino acids,
and also any peptides matching to another human gene or protein.
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